An Open Label Study of V81444 Using Positron Emission Tomography to Assess Occupancy of Brain Adenosine A2A Receptors & Functional & Perfusion MRI to Explore Effects on Regional Brain Activity & Perfusion in Healthy Male Volunteers.
Phase of Trial: Phase I
Latest Information Update: 10 May 2016
At a glance
- Drugs CPI 444 (Primary)
- Indications Parkinson's disease
- Focus Pharmacodynamics
- Sponsors Vernalis
- 12 Dec 2012 Positive results were reported in a Vernalis media release.
- 12 Dec 2012 Status changed from recruiting to completed, as reported by Vernalis.
- 22 Aug 2012 Results are expected by the end of 2012 according to a Vernalis media release.